Busulfan (Busulfex)

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Also Known As:

Networked: 2106 relevant articles (179 outcomes, 282 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Andersson, Borje S: 42 articles (01/2021 - 01/2002)
2.	Champlin, Richard E: 35 articles (01/2022 - 01/2002)
3.	Mohty, Mohamad: 32 articles (01/2022 - 07/2003)
4.	Nagler, Arnon: 27 articles (01/2022 - 01/2003)
5.	Blaise, Didier: 25 articles (01/2021 - 07/2003)
6.	Labopin, Myriam: 24 articles (01/2022 - 10/2013)
7.	Kebriaei, Partow: 21 articles (01/2022 - 03/2011)
8.	Nieto, Yago: 20 articles (01/2022 - 03/2011)
9.	Popat, Uday: 20 articles (01/2022 - 03/2011)
10.	Valdez, Benigno C: 18 articles (01/2022 - 11/2008)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2023 - "We aimed to compare retrospectively, total body irradiation (12 Gy) plus Flu (FluTBI12) versus busulfan (Bu) plus Flu (FB4) as a myeloablative conditioning before allo-HCT in patients with acute myeloid leukemia (AML). " 03/01/2013 - "A wide range of busulfan exposures were targeted for children with the same disease (eg, 39 target busulfan exposures for the 264 children diagnosed with acute myeloid leukemia). " 02/01/2005 - "Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD. " 01/01/2002 - "Sixty patients with advanced MDS or acute myeloid leukemia evolving from MDS (sAML), 12 to 62 years old (median, 40 years), were conditioned with busulfan (7 mg/kg) and TBI (6 x 200 cGy) (BU/TBI) and received transplants from related (n = 20) or unrelated donors (n = 40). " 09/01/2000 - "Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia."
2.	Leukemia 01/01/2021 - "Trends toward improved survival were seen in patients transplanted for myeloid disease using bone marrow as stem cell source who achieved a busulfan AUC > 4000 μmol*min/day with two-year relapse-free survival approaching 80% CONCLUSIONS: This conditioning regimen is safe and effective in patients with high-risk leukemias, particularly myeloid disease. " 11/01/1996 - "Children with inherited disorders eliminated busulphan significantly faster after the first and the last dose with half-lives (t1/2) of 1.93 and 1.71 h, respectively compared to children with leukemia (3.16 and 2.70 h, respectively). " 01/01/2015 - "In this study, we investigated the cytotoxic effects and underlying mechanisms in leukemia stem-like KG1a cells exposed to busulfan (BUS) and CUR, either alone or in combination. " 01/01/2022 - "Here we compared the outcomes in children and adolescents with high-risk acute leukemia who underwent HRD HSCT with PTCy (n = 35) or MUD HSCT (n = 45) after targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring. " 10/01/2020 - "We retrospectively analyzed in a population of 670 children receiving allo-HSCT for acute leukemia the occurrence of different late effects in function of the choice made between total body irradiation (TBI) and busulfan, as part of the preparative regimen. "
3.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/01/1989 - "[Appearance of chromosomally normal hemopoiesis during busulfan-induced remission in a case of Ph1 positive chronic myelogenous leukemia]." 01/01/1985 - "Survival in 73 patients with Ph1-positive chronic myelocytic leukemia was correlated with remission duration and leukocyte doubling time after initial treatment with busulfan and also, with clinical and laboratory features recorded at the time of diagnosis. " 01/01/1966 - "Prolonged remission in chronic myeloid leukemia after one course of busulfan." 07/01/1965 - "Prolonged remission in chronic myeloid leukemia after a single course of myleran." 05/01/1989 - "[A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan]."
4.	Neoplasms (Cancer) 09/01/1994 - "This study investigated the toxicity and efficacy of busulfan-containing pre-transplant regimens in patients with solid tumors. " 01/01/2018 - "These results validate the hierarchy of blood cells likely targeted by busulfan, and based on these findings, clinical trials using myelotoxic but not myeloablative doses of intravenous busulfan will be designed for patients with myeloid malignancies." 01/01/2024 - "The incidence of busulfan-related secondary malignancies is low, and likely to be substantially less than 1% in pediatric transplant recipients, especially those receiving busulfan monotherapy for nonmalignant conditions other than SCD." 01/01/2024 - "We conducted a literature-based assessment of busulfan and subsequent late effects, with emphasis on secondary malignancies, identifying publications via PubMed searches, and selecting those reporting at least 3 years of follow-up. " 01/01/2024 - "The incidence of secondary malignancies associated with busulfan exposure is considered low, but has been poorly characterized. "
5.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/01/2021 - "A myeloablative, fractionated busulfan regimen reduces relapse and improves survival without increasing NRM in older patients with AML and myelodysplastic syndrome." 06/01/1994 - "Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes." 09/01/2016 - "Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes." 01/01/2002 - "Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality." 04/15/1993 - "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS). "

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	fludarabine
3.	Melphalan (Alkeran)
4.	Thiotepa (Triethylenethiophosphoramide)
5.	Etoposide (VP 16)
6.	Hydroxyurea (Hydrea)
7.	Antilymphocyte Serum (Anti-Thymocyte Globulin)
8.	Cytarabine (Cytosar-U)
9.	Interferon-alpha (Interferon Alfa)
10.	Idarubicin (4 Demethoxydaunorubicin)

Related Therapies and Procedures

1.	Hematopoietic Stem Cell Transplantation
2.	Stem Cell Transplantation
3.	Transplantation
4.	Drug Therapy (Chemotherapy)
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)